NCT02637947

Brief Summary

The study purpose is to demonstrate that ventricular tachycardia (VT) ablation using the Niobe™ ES system results in superior outcomes compared to a manual approach in subjects with ischemic scar VT in a low ejection fraction population.

Trial Health

63
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
182

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Jan 2016

Longer than P75 for not_applicable

Geographic Reach
7 countries

16 active sites

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 4, 2015

Completed
18 days until next milestone

First Posted

Study publicly available on registry

December 22, 2015

Completed
10 days until next milestone

Study Start

First participant enrolled

January 1, 2016

Completed
6.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 15, 2022

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

February 15, 2022

Completed
Last Updated

September 27, 2022

Status Verified

September 1, 2022

Enrollment Period

6.1 years

First QC Date

December 4, 2015

Last Update Submit

September 23, 2022

Conditions

Outcome Measures

Primary Outcomes (1)

  • freedom from any VT in the overall cohort

    12 months

Secondary Outcomes (4)

  • acute success of procedure

    at end of procedure (immediate)

  • freedom from VT in large scar subpopulation

    12 months

  • major adverse events

    48 hours post-procedure

  • mortality rate

    12 months

Other Outcomes (10)

  • Total number of appropriate ICD defibrillator shocks

    12 months

  • Total number of ICD applications of anti-tachycardia pacing

    12 months

  • Total procedure time (skin to skin)

    through end of acute procedure, an average of 3 hours

  • +7 more other outcomes

Study Arms (2)

Magnetic navigation

EXPERIMENTAL

Catheter ablation using magnetic navigation for ventricular tachycardia via remote magnetic navigation of a NaviStar RMT ThermoCool catheter, or other magnetically compatible catheter, via Stereotaxis's Niobe ES system.

Device: catheter ablation using magnetic navigation

Manual navigation

ACTIVE COMPARATOR

Catheter ablation using manual navigation for ventricular tachycardia via a manually navigated Thermocool catheter, or equivalent catheter.

Device: catheter ablation using manual navigation

Interventions

elimination of cardiac arrhythmias through heating and destroying heart tissue with faulty electrical pathways through the use of Stereotaxis's Niobe ES System with the NaviStar RMT ThermoCool catheter or other magnetically compatible catheters.

Magnetic navigation

elimination of cardiac arrhythmias through heating and destroying heart tissue with faulty electrical pathways through the use of the NaviStar ThermoCool catheter or other manually navigated catheters.

Manual navigation

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • subject has had an ICD previously implanted
  • subject has drug-refractory monomorphic VT
  • subject is a candidate for ischemic VT RF ablation
  • subject has had a myocardial infarction
  • subject has a LVEF less than or equal to 35%

You may not qualify if:

  • subject has non-ischemic VT
  • subject has a history of stroke within 1 month prior to enrollment
  • subject has had an acute myocardial infarction within 30 days prior to enrollment
  • subject has unstable angina
  • subject has undergone cardiac surgery within 60 days prior to enrollment
  • subject is pregnant or nursing
  • subject has a limited life expectancy of 1 year or less (Subjects requiring LVAD/IABP intraprocedural support may be enrolled as long as life expectancy is at least 1 year following the ablation procedure.)
  • subject is unable or unwilling to cooperate with study procedures
  • subject has a known presence of intracardiac thrombi as determined by echocardiography
  • subject has a major contraindication to anticoagulation therapy or coagulation disorder
  • subject has had a previous pericarditis or cardiac tumor
  • subject has had previous thoracic radiation therapy
  • any other reason the investigator considers the subject ineligible

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (16)

Florida Hospital

Orlando, Florida, 32803, United States

Location

Augusta University

Augusta, Georgia, 30912, United States

Location

University of Chicago Medical Center

Chicago, Illinois, 60637, United States

Location

Advocate Christ Medical Center

Oak Lawn, Illinois, 60453, United States

Location

The University of Kansas Medical Center

Kansas City, Kansas, 66160, United States

Location

Weill Cornell Medical

New York, New York, 10065, United States

Location

Texas Cardiac Arrhythmia Research Foundation

Austin, Texas, 78705, United States

Location

Intermountain Heart Institute

Murray, Utah, 84107, United States

Location

Westmead Hospital

Westmead, New South Wales, 2145, Australia

Location

AZ Sint-Jan

Bruges, West Flanders, 8000, Belgium

Location

ZNA Middelheim

Antwerp, Belgium

Location

Na Homolce Hospital

Prague, 15030, Czechia

Location

Rigshospitalet

Copenhagen, Denmark

Location

Chu De Nancy - Hôpitaux De Brabois

Nancy, France

Location

Onze Lieve Vrouwe Gasthuis (OLVG)

Amsterdam, Netherlands

Location

Erasmus Medical Center

Rotterdam, Netherlands

Location

Related Publications (1)

  • Di Biase L, Tung R, Szili-Torok T, Burkhardt JD, Weiss P, Tavernier R, Berman AE, Wissner E, Spear W, Chen X, Neuzil P, Skoda J, Lakkireddy D, Schwagten B, Lock K, Natale A; MAGNETIC VT investigators. MAGNETIC VT study: a prospective, multicenter, post-market randomized controlled trial comparing VT ablation outcomes using remote magnetic navigation-guided substrate mapping and ablation versus manual approach in a low LVEF population. J Interv Card Electrophysiol. 2017 Apr;48(3):237-245. doi: 10.1007/s10840-016-0217-3. Epub 2017 Jan 7.

MeSH Terms

Conditions

Tachycardia, Ventricular

Condition Hierarchy (Ancestors)

TachycardiaArrhythmias, CardiacHeart DiseasesCardiovascular DiseasesCardiac Conduction System DiseasePathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Andrea Natale, MD

    Texas Cardiac Arrhythmia Research Foundation

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

December 4, 2015

First Posted

December 22, 2015

Study Start

January 1, 2016

Primary Completion

February 15, 2022

Study Completion

February 15, 2022

Last Updated

September 27, 2022

Record last verified: 2022-09

Locations